Circulation (2004) 109(8):9625
The peer-reviewed findings will be presented on Saturday (June 13) at ENDO 2026, the Endocrine Society's annual meeting
FDA inspections like these are a cornerstone of U.S
Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials
In a randomized, placebo-controlled study, pemvidutide, a dual GLP-1/GCG receptor agonist, significantly decreased liver fat content by up to 68.5% after 12 weeks of treatment, accompanied by reductions in hepatic inflammation markers and body weight, highlighting the potential of dual receptor agonists to modify MASLD pathophysiology (47)
The withdrawal process from semaglutide can also trigger its own round of telogen effluvium as the body readjusts to eating without pharmaceutical appetite suppression